| Literature DB >> 29129877 |
Yuko Toishi1,2, Nobuo Tsunoda1, Shun-Ichi Nagata3, Rikio Kirisawa2, Kentaro Nagaoka4,5, Gen Watanabe4,5, Yojiro Yanagawa6, Seiji Katagiri6, Kazuyoshi Taya1,4.
Abstract
Testosterone (T) concentration is a useful indicator of reproductive function in male animals. However, T concentration is not usually measured in veterinary clinics, partly due to the unavailability of reliable and rapid assays for animal samples. In this study, a rapid chemiluminescent enzyme immunoassay system (CLEIA system) that was developed for the measurement of T concentration in humans use was validated for stallion blood samples. First, serum T concentrations were measured using the CLEIA system and compared with those measured by a fluoroimmunoassay that has been validated for use in stallions. The serum T concentrations measured by the two methods were highly correlated (r = 0.9865, n = 56). Second, to validate the use of whole blood as assay samples, T concentrations in whole blood and in the serum were measured by the CLEIA system. T concentrations in both samples were highly correlated (r = 0.9665, n = 64). Finally, to evaluate the practical value of the CLEIA system in clinical settings, T concentrations were measured in three stallions with reproductive abnormalities after the administration of human chorionic gonadotropin (hCG). Two stallions with small or absent testes in the scrotum showed an increase in T production in response to hCG administration and one stallion with seminoma did not. In conclusion, the CLEIA system was found to be a rapid and reliable tool for measuring T concentrations in stallions and may improve reproductive management in clinical settings and in breeding studs.Entities:
Keywords: Chemiluminescent enzyme immunoassay; Cryptorchidism; Reproductive abnormalities; Stallions; Testosterone
Mesh:
Substances:
Year: 2017 PMID: 29129877 PMCID: PMC5830357 DOI: 10.1262/jrd.2017-099
Source DB: PubMed Journal: J Reprod Dev ISSN: 0916-8818 Impact factor: 2.214
Breed, age, clinical signs, and hCG challenge protocol of stallions in Study 1
| Stallion No. | Breed | Age | hCG Dosage (IU) | Clinical findings | Date |
| 1 | Warmblood | 2 | 10,000 | No clinical symptom | 2010/9/23 |
| 2 | Warmblood | 2 | 10,000 | No clinical symptom | 2010/9/23 |
| 3 | Warmblood | 2 | 10,000 | No clinical symptom | 2010/10/4 |
| 4 | Halfbred | 3 | 10,000 | No clinical symptom | 2010/10/7 |
Breed, age, and T administration protocol of stallions in Study 2
| Stallion No. | Breed | Age | Dosage per treatment | No. of days for daily treatments | Period of daily blood collection | Date |
| 5 | Halfbred | 7 | 100 mg | 1 | Day 0 to 7 | 2013/1/7 |
| 6 | Warmblood | 4 | 100 mg | 2 | Day 0 to 7 | 2013/1/7 |
| 7-1st | Warmblood | 4 | 250 mg | 1 | Day 0 to 8 | 2013/1/7 |
| 7-2nd a | 250 mg | 4 | Day 0 to 14 | 2013/2/23 | ||
| 8-1st | Halfbred | 6 | 250 mg | 2 | Day 0 to 8 | 2013/1/7 |
| 8-2nd a | 250 mg | 4 | Day 0 to 14 | 2013/2/23 |
a The second T enanthate treatment for both stallions 7 and 8 were started 47 days after the first day of the first treatment.
Breed, age, clinical signs and hCG challenge protocol of stallions in Study 3
| Stallion No. | Breed | Age | hCG Dosage | Clinical findings | Date |
| 9 | Thoroughbred | 9 | 5,000 | Small size testes, left: 6.4 × 2.9 × 2.7 (cm), right: 7.6 × 4.1 × 2.7 (cm) a | 2011/1/8 |
| 10 | Haflinger | 26 | 10,000 | Enlarged testes suspected tumor, left: 19.4 × 13.0 × 10.2 (cm), right: 20.8 × 14.0 × 12.0 (cm) a | 2013/1/29 |
| 11 b | Warmblood | 3 | 10,000 | Absence of testes in the scrotal, suspected cryptorchidism or castrated | 2015/9/4 and 2015/11/17 |
a Testicular sizes are indicated as length × height × width (cm). b Stallion 11 was administered 10,000 IU of hCG twice with an interval of two months.
Fig. 1.Correlation of serum testosterone (T) concentrations measured by the chemiluminescent enzyme immunoassay (CLEIA) system and by fluoroimmunoassay (FIA). Stallions 1 to 4 were administered 10,000 IU of human chorionic gonadotrophin (hCG) intravenously, and T concentrations in blood samples (n = 56) were measured by the CLEIA system and FIA. T concentrations measured by the two methods were strongly correlated (r = 0.9865).
Fig. 2.Comparison of testosterone (T) concentrations measured by the chemiluminescent enzyme immunoassay (CLEIA) system and by fluoroimmunoassay (FIA). Four stallions (1 to 4) that presented no clinical signs were administered 10,000 IU of human chorionic gonadotrophin (hCG). T concentrations in serum samples were measured by the CLEIA system and by FIA. In the figures, T concentrations are shown as averages ± standard error of the mean. The left vertical axis shows hourly data and the right vertical axis shows daily data. “*” indicates that the mean of T concentrations is significantly higher than that before administration.
Fig. 3.Correlation of testosterone (T) concentrations in whole blood and serum as measured by the chemiluminescent enzyme immunoassay (CLEIA) system. Stallions 5 to 8 were administered (i. m.) T enanthate (100 or 250 mg) for one to four days (daily). Blood samples (n = 64) were collected before and after T enanthate administration for 5 to 8 consecutive days. See Table 2 for details of the T enanthate treatment protocol in each stallion.
Fig. 4.Concentrations of testosterone (T) in whole blood after T enanthate administration. Stallions 5 to 8 were administered T enanthate as shown in Table 2. Arrows indicate administration of T enanthate.
Fig. 5.Changes in serum testosterone (T) concentrations (ng/ml) after human chorionic gonadotropin (hCG) administration in stallions with reproductive abnormalities. Stallion 9 (5,000 IU) and stallions 10 and 11 (10,000 IU) were administered hCG to determine T responses to hCG administration. See Table 3 for clinical findings of each animal. Stallion 11 was administered hCG twice with a two-month interval.